A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.
Willing to sign an ICF, able to comprehend and comply with the study procedures.
Male or female subjects aged 18 to 65，inclusive.
Subjects with a clinical diagnosis of non-segmental vitiligo.
Agree to stop all other treatments for vitiligo during the study period.
Diagnosed as other active depigmentation disease.
At screening or baseline visits, subject exhibits active inflammatory dermatologic disease or symptoms that in the opinion of investigators would interfere of vitiligo evaluation or response to treatment.
Uncontrolled thyroid function at screening as determined by the investigator.
Use of permanent depigmentation treatment or skin grafts.
CSPC Ouyi Pharmaceutical Co., Ltd.
Lead sponsor
Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.
Collaborator